New board member at Oxygen Biotherapeutics
This article was originally published in Scrip
Melville Engel has joined the board of Oxygen Biotherapeutics. Mr Engel has 27 years' experience in leading large and small companies, and previously served in senior executive positions with Merck Generics Group, a division of Merck KGaA, and Allergan.
You may also be interested in...
The US FDA has given the go-ahead for marketing of ViiV healthcare’s novel HIV drug just as the EMA removes the accelerated assessment status from its application there.
Executives On The Move: BioXcel Therapeutics Picks A Development Officer, A Finance Hire At RenovaCare And CANbridge Taps Takeda Talent
Immuno-oncology and neuroscience firm BioXcel Therapeutics picks a chief development officer, and stem-cell therapy company RenovaCare hires a CFO. Plus, CANbridge Life Sciences, developer of specialty health products, adds Takeda Pharma rare disease lead as global head, business development.
Topline Phase II data for the antibody-drug conjugate tisotumab vedotin put it on a swift path towards approval in cervical cancer.